ACR appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 6, 2011, Pages 636-647

  Moran, Brian J ^a,n   Derose, Paul ^b   Hsu, I Chow Joe ^d   Abdel Wahab, May ^g   Arterbery, V Elayne ^h   Ciezki, Jay P ⁱ   Frank, Steven J ^c   Mohler, James Lloyd ^j,k   Rosenthal, Seth A ^e   Rossi Jr , Carl J ^f   Yamada, Yoshiya ^l   Merrick, Gregory S ^m  

^a Chicago Prostate Cancer Center   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Radiological Associates of Sacramento Medical Group Inc   (United States)

^f LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h Karmanos Crittenton Cancer Center   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

^k American Urology Association   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m WHEELING JESUIT UNIVERSITY   (United States)

ⁿ AMERICAN COLLEGE OF RADIOLOGY   (United States)

more..

Author keywords

appropriateness criteria; external beam radiation therapy; prostate cancer; quality of life; standard of care

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER STAGING; CONSENSUS DEVELOPMENT; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MORBIDITY; PATIENT SELECTION; PHYSICIAN; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; RADIATION DOSE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 81855228737     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182354a65     Document Type: Review

References (105)

1. Consensus statement: the Management of Clinically Localized Prostate Cancer. National Institutes of Health Consensus Development Panel. NCI Monogr. 1988;7:3-6.
2. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA. 1997;277:467-471.
3. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719.
4. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
5. D'Amico AV, Schultz D, Silver B, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:679-684.
6. Perez AA, Pilepich MV, Zivnuska F. Tumor control in definitive irradiation of localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1986;12:523-531.
7. Perez CA, Lee HK, Georgiou A, et al. Technical and tumorrelated factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993;26:581-591.
8. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988; 15:1299-1305.
9. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53: 1097-1105.
10. McGowan DG. The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1981;7: 1333-1339.
11. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003; 21:1904-1911.
12. Lawton CA, DeSilvio M, Roach M 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646-655.
13. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? preliminary results of GETUG-01. J Clin Oncol. 2007;25: 5366-5373.
14. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29-33.
15. Kuban DA, Thames HD, Levy LB, et al. Long-term multiinstitutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003; 57:915-928.
16. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
17. Kupelian PA, Mohan DS, Lyons J, et al. Higher than standard radiation doses (Z72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;46:567-574.
18. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166:876-881.
19. Zietman AL. Correction: inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA. 2008;299:898-899.
20. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16:275-283.
21. Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:421-432.
22. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007;177: 2151-2156; discussion 2156.
23. Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:2517-2526.
24. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000; 92:1582-1592.
25. Hanks GE, Schultheiss TE, Hunt MA, et al. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1995;31:25-29.
26. Sandler HM, McLaughlin PW, Ten Haken RK, et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys. 1995;33: 797-801.
27. Lee WR, Hanks GE, Hanlon AL, et al. Lateral rectal shielding reduces late rectal morbidity following high dose threedimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys. 1996;35:251-257.
28. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998; 41:491-500.
29. Lu Y, Song PY, Li SD, et al. A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1995;33: 1121-1125.
30. Dale E, Olsen DR, Fossa SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:385-391.
31. Roach M, Winter K, Michalski JM, et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;60:1351-1356.
32. Mantz CA, Song P, Farhangi E, et al. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:551-557.
33. Incrocci L, Koper PC, Hop WC, et al. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapyfor prostate cancer: a randomized, ouble-blind, placebocontrolled, cross-over study. Int J Radiat Oncol Biol Phys. 2001; 51:1190-1195.
34. Weber DC, Bieri S, Kurtz JM, et al. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol. 1999;17: 3444-3449.
35. Hanks GE. More on the Uro-Oncology Research Group report of radical surgery versus radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1988;14:1053-1054.
36. Paulson DF. More on the Uro-Oncology Research Group report of radical surgery versus radiotherapy for adenocarcinoma of the prostate: Rebuttal (Letter). Int J Radiat Oncol Biol Phys. 1988;14:1053-1054.
37. Paulson DF. Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. NCI Monogr. 1988; 127-131.
38. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982; 128:502-504.
39. Pilepich MV, Bagshaw MA, Asbell SO, et al. Definitive radiotherapy in resectable (stage A2 and B) carcinoma of the prostate-results of a nationwide overview. Int J Radiat Oncol Biol Phys. 1987;13:659-663.
40. Zietman AL, Shipley WU. Randomized trials in loco-regionally confined prostate cancer: past, present, and future. Semin Radiat Oncol. 1993;3:210-220.
41. Hanks GE, Hanlon AL, Schultheiss TE, et al. Conformal external beam treatment of prostate cancer. Urology. 1997;50:87-92.
42. Perez CA, Cosmatos D, Garcia DM, et al. Irradiation in relapsing carcinoma of the prostate. Cancer. 1993;71(3 Suppl): 1110-1122.
43. D'Amico AV, Whittington R, Kaplan I, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4 to 20 ng/mL. Int J Radiat Oncol Biol Phys. 1997;37:1053-1058.
44. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
45. Vicini FA, Martinez A, Hanks G, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002;95: 2126-2135.
46. Aizer AA, Yu JB, Colberg JW, et al. Radical prostatectomy versus intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009;93: 185-191.
47. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
48. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988;139:766-772.
49. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
50. Perez CA. Carcinoma of the prostate: a model for management under impending health care system reform. 1994 RSNA annual oration in radiation oncology. Radiology. 1995;196:309-322.
51. Hanks GE, Krall JM, Pilepich MV, et al. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: implications of RTOG data for patient management and trial design and stratification. Int J Radiat Oncol Biol Phys. 1992; 23:293-298.
52. Stein A, deKernion JB, Smith RB, et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 1992;147(3 Pt 2): 942-946.
53. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150: 110-114.
54. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843-848.
55. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
56. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000; 18:3352-3359.
57. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747-752.
58. Frazier HA, Robertson JE, Humphrey PA, et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 1993;149:516-518.
59. Zincke H, Blute ML, Fallen MJ, et al. Radical prostatectomy for stage a adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol. 1991;146:1053-1058.
60. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997; 37:1035-1041.
61. Roach M 3rd, Hanks G, Thames H Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
62. Zagars GK, Pollack A, Kavadi VS, et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995;32:293-306.
63. Rosser CJ, Kuban DA, Levy LB, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002;168:2001-2005.
64. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
65. Jhaveri FM, Zippe CD, Klein EA, et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54:884-890.
66. Lichter AS, Sandler HM, Robertson JM, et al. Clinical experience with three-dimensional treatment planning. Semin Radiat Oncol. 1992;2:257-266.
67. Leibel SA, Zelefsky MJ, Kutcher GJ, et al. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol. 1994;152(5 Pt 2):1792-1798.
68. Corn BW, Hanks GE, Schultheiss TE, et al. Conformal treatment of prostate cancer with improved targeting: superior prostatespecific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys. 1995;32:325-330.
69. Hanks GE, Schultheiss TE, Hanlon AL, et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys. 1997;37:543-550.
70. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116.
71. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176(4 Pt 1): 1415-1419.
72. Matzinger O, Duclos F, van den Bergh A, et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localized prostate cancer in the EORTC trial 22991. Eur J Cancer. 2009; 45:2825-2834.
73. Lips I, Dehnad H, Kruger AB, et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy versus 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys. 2007;69:656-661.
74. Al-Mamgani A, Heemsbergen WD, Peeters ST, et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:685-691.
75. Chung HT, Xia P, Chan LW, et al. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. 2009;73:53-60.
76. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239.
77. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;28:1106-1111.
78. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67-74.
79. Jabbari S, Weinberg VK, Shinohara K, et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus highdose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys. 2010;76:36-42.
80. Balter JM, Lam KL, Sandler HM, et al. Automated localization of the prostate at the time of treatment using implanted radiopaque markers: technical feasibility. Int J Radiat Oncol Biol Phys. 1995;33:1281-1286.
81. Lattanzi J, McNeeley S, Pinover W, et al. A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys. 1999;43:719-725.
82. Zietman AL, Shipley WU, Willett CG. Residual disease after radical surgery or radiation therapy for prostate cancer: clinical significance and therapeutic implications. Cancer. 1993; 71(3 Suppl):959-969.
83. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol. 1995;154(2 Pt 1):456-459.
84. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475-487.
85. Zietman AL, Prince EA, Nakfoor BM, et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997;38:1067-1070.
86. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:247-252.
87. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
88. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-longterm results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-1290.
89. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
90. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609-615.
91. Warde P, Mason MR, Sydes MK, et al. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). J Clin Oncol. 2010;28:18s. (suppl; abstr CRA4504).
92. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516-2527.
93. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation versus radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289-295.
94. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6:841-850.
95. Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004;171: 1137-1140.
96. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424-1430.
97. Marzi S, Saracino B, Petrongari MG, et al. Modeling of alpha/ beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res. 2009;28:117.
98. Coote JH, Wylie JP, Cowan RA, et al. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys. 2009;74: 1121-1127.
99. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;69:1084-1089.
100. Lim TS, Cheung PC, Loblaw DA, et al. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys. 2008;72:85-92.
101. Norkus D, Miller A, Plieskiene A, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response. Medicina (Kaunas). 2009;45:469-475.
102. Leborgne F, Fowler J. Late outcomes following hypofractionated conformal radiotherapy versus standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison. Int J Radiat Oncol Biol Phys. 2009;74:1441-1446.
103. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099-1105.
104. Tang CI, Loblaw DA, Cheung P, et al. Phase I/II study of a fivefraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol). 2008;20:729-737.
105. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043-1048.